TrialBlood2022

Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.

Alexander E Perl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.